XLO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	375 405
Średni wolumen	1.22M
Kapitalizacja rynkowa	38.39M
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $-0.300 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.370
ATR14	$0.00800 (0.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Gilead Sciences, Inc.	Buy	485 250	Common Stock
2024-04-02	Gilead Sciences, Inc.	Buy	3 882 450	Prefunded Warrants (right to buy)
2024-03-27	Gilead Sciences, Inc.	Sell	0	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	733	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	267	Common Stock

INSIDER POWER
91.69
Last 95 transactions
Buy: 18 066 351 \| Sell: 51 747 162

Wolumen Korelacja

Długi: 0.03 (neutral)

Krótki: -0.80 (strong negative)

Signal:(38.412) Neutral

Xilio Therapeutics, Inc. Korelacja

10 Najbardziej pozytywne korelacje
AMRB	0.872
OTRK	0.864
NEON	0.858
SHYF	0.843
PPTA	0.841
POET	0.825
UBFO	0.825
LWAC	0.82
PBPB	0.82
NVCN	0.819

10 Najbardziej negatywne korelacje
TUEM	-0.819
STAB	-0.818
CFV	-0.812
AHPI	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xilio Therapeutics, Inc. Korelacja - Waluta/Towar

0.17
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.26
( neutral )

Xilio Therapeutics, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2023
Przychody:	$0
Zysk brutto:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2022
Przychody:	$0
Zysk brutto:	$-1.85M (0.00 %)
EPS:	$-3.19

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-13.52

Financial Reports:

No articles found.

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.